Clinical TrialAug 10, 2026, 07:17 AM
Sionna Therapeutics SION-719 Trial Fails; Preserves Capital
AI Summary
Sionna Therapeutics announced topline data from its PreciSION CF Phase 2a trial of SION-719 and its Phase 1 trial of SION-451 dual combinations. The SION-719 trial, evaluating it as an add-on to standard of care for cystic fibrosis, did not meet its key activity endpoint of sweat chloride reduction. Consequently, the company will not advance SION-719 as an add-on to standard of care and plans to preserve capital while evaluating next steps for its SION-451 program, which met safety and pharmacokinetic objectives in healthy subjects. The company ended Q2 with approximately $268.3 million in cash.
Key Highlights
- SION-719 Phase 2a trial did not meet key activity endpoint of sweat chloride reduction (-1.0 mmol/L mean placebo-adjusted change).
- Sionna Therapeutics will not advance SION-719 as an add-on to standard of care.
- SION-451 Phase 1 trial met safety, tolerability, and pharmacokinetic objectives in healthy subjects.
- SION-451 + SION-2222 was identified as the preferred dual combination.
- Company ended Q2 with approximately $268.3 million in cash, cash equivalents, and marketable securities.
- Sionna Therapeutics plans to take actions to preserve capital while evaluating next steps for SION-451.
Price Impact
More from SION